SELP-100

SELP-100 (also known as TSGL-Ig) is a recombinant tandem P-selectin glycoprotein ligand-1 (PSGL-1) immunoglobulin fusion protein being developed by Quell Pharma and Aqualung Therapeutics. It consists of two P-selectin sulfated-glycopeptide-binding domains in a tandem configuration fused to an inactivated human IgG1 Fc domain, creating a dimer with four selectin-binding sites. SELP-100 acts as a competitive pan-selectin antagonist, binding to P-selectin, E-selectin, and L-selectin to block leukocyte-endothelial adhesion and transendothelial migration. It is under preclinical development for the treatment of acute inflammatory and fibrotic diseases, including acute respiratory distress syndrome (ARDS), ventilator-induced lung injury (VILI), sepsis, and vaso-occlusive crises in sickle cell disease (SCD).

Other names

recombinant tandem PSGL-1 immunoglobulin fusion moleculetandem P-selectin glycoprotein ligand immunoglobulintandem P-selectin glycoprotein ligand-1 immunoglobulinTSGL